IVVD
Invivyd Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$364.55M
P/E Ratio
—
EPS
$-0.30
Beta
0.74
52W High
$3.07
52W Low
$0.46
50-Day MA
$1.64
200-Day MA
$1.56
Dividend Yield
—
Profit Margin
-98.30%
Forward P/E
31.85
PEG Ratio
—
About Invivyd Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $53.43M |
| Gross Profit (TTM) | $49.68M |
| EBITDA | $-54.80M |
| Operating Margin | -73.00% |
| Return on Equity | -34.00% |
| Return on Assets | -17.10% |
| Revenue/Share (TTM) | $0.31 |
| Book Value | $0.86 |
| Price-to-Book | 1.49 |
| Price-to-Sales (TTM) | 6.83 |
| EV/Revenue | 2.548 |
| EV/EBITDA | 0.78 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 24.50% |
| Shares Outstanding | $282.60M |
| Float | $167.59M |
| % Insiders | 11.28% |
| % Institutions | 92.16% |
Analyst Ratings
Consensus ($10.00 target)
3
Buy1
HoldData last updated: 4/8/2026